NovaBay Pharmaceuticals Inc
AMEX:SDEV
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
N
|
NovaBay Pharmaceuticals Inc
AMEX:SDEV
|
US |
|
Fineqia International Inc
F:FNQA
|
CA |
|
R
|
Radici Pietro Industries & Brands SpA
MIL:RAD
|
IT |
|
S
|
Surface Metals Inc
CNSX:SUR
|
CA |
|
T
|
TDK Corp
F:TDK
|
JP |
|
T
|
Teixeira Duarte SA
SWB:TXC2
|
PT |
|
E
|
Eastern Commercial Leasing PCL
SET:EAST
|
TH |
|
T
|
Thai Rubber Latex Group PCL
SET:TRUBB
|
TH |
|
G
|
Golcap Resources Corp
F:2SO0
|
CA |
|
C
|
CCL Industries Inc
OTC:CCDBF
|
CA |
Ergebniskonferenzen
Letzter Earnings Call
Record sales: NovaBay said Avenova ordered sales hit all-time highs on Amazon in March and April, with April sales more than 20% higher than a year ago.
Q1 growth: First-quarter total sales rose 12% to $2.6 million, driven mainly by stronger online Avenova sales.
Efficiency gains: Sales and marketing expense fell 50% to $1.1 million even as online sales improved, reflecting more efficient digital advertising.
Strategic shift: Management emphasized the company’s move to focus on eyecare and the dry eye market, which it described as large and growing.
New partnership: NovaBay completed training with Eyenovia and expects the co-marketing launch of clobetasol in the third quarter.
Profit impact: Net loss widened to $3.6 million, largely reflecting a noncash divestiture loss and other financing-related items.